对SLCO1B1变异对他类药物的有效性影响的回顾性评估
Mayeesha Ahmed Feldman1,2, Kendall Billman2, Mounia Sennoun3
1Department of Pharmacy, St. Elizabeth Healthcare, Edgewood, KY 41017, USA.
Journal of personalized medicine
|November 26, 2025
概括
溶质载体有机离子载体家族成员1B1 (SLCO1B1) 的遗传变异没有影响LDL-C降低或与他类药物相关的肌肉症状 (SAMS). 这项研究表明,SLCO1B1基因型不会显著改变他类药物降低胆固醇的有效性.
科学领域:
- 药物基因组学 药物基因组学
- 心血管医学 心血管医学
- 药物新陈代谢 药物新陈代谢
背景情况:
- 溶质载体有机离子载体家族成员1B1 (SLCO1B1) 对于肝细胞中他类药物的吸收至关重要.
- 虽然SLCO1B1变异对他类药物相关肌肉症状 (SAMS) 的影响已知,但其对降低LDL-C的影响不明.
研究的目的:
- 调查SLCO1B1遗传变异是否影响他类药物降低LDL-C水平的有效性.
- 评估SLCO1B1表型与LDL-C降低,SAMS发生和他类药物坚持之间的关联.
主要方法:
- 这是一项对213名成年人进行的回顾性队列研究.
- 针对SLCO1B1变体rs4149056 (NM_006446.5:c.521T>C) 的基因定型,将患者分为正常,下降或差的SLCO1B1功能组.
- 主要终点:从基线到随访期间的LDL-C百分比变化 (在开始服用他后≥6周). 二级终点:SAMS发生率和他类药物的坚持.
主要成果:
- 在所有参与者中,总体LDL-C降低平均为32%.
- 不同的SLCO1B1功能表型之间没有观察到LDL-C降低的统计学意义上的差异 (p = 0.24).
- SLCO1B1变异没有显著影响SAMS发生或他类药物坚持.
结论:
- SLCO1B1遗传变异似乎不会显著影响他类药物降低LDL-C的有效性.
- 该研究没有发现SLCO1B1表型与SAMS或他类药物坚持之间存在显著的关联.
- 限制包括追溯设计和有限的坚持数据,需要前性验证研究.
相关概念视频
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.3K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.3K
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
241
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
241
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
387
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
387
01:21Factors Affecting Drug Response: Overview
2.8K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
2.8K
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
170
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
170
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
186
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
186